The human melanoma cell line WM266.4 was kindly provided by the Department of Medical Biochemistry of the Jagiellonian University Medical College (Kraków, Poland) in 2006 and authenticated in 2021 using STR profiling with Identifiler Plus (ABI) and an
ABI 3130xl Genetic Analyzer (Applied Biosystems, Waltham, MA, USA). Human melanoma cell line A375 was obtained from the American Type Culture Collection (CRL_1619, ATCC, Manassas, VA, USA) in 2020. Both cell lines were cultured in RPMI1640 containing 10%
FBS (Gibco, Thermo Fisher Scientific, Waltham, MA, USA),
penicillin 150 U/ml (Sigma-Aldrich, St. Louis, MO, USA), and
streptomycin 100 µg/mL (Sigma-Aldrich, St. Louis, MO, USA) at 37 °C at 5% CO
2 and 95% humidity.
TNF-α (100 ng/mL, Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 0.1% BSA/ PBS, aliquoted, and stored at − 20 °C. For ELISA analysis, the cell culture medium was replaced with serum-free medium and
TNF-α (10 ng/mL) was added 24 h, while for qRT-PCR,
TNF-α was added to the complete media for 3 h. The effect of p38 MAPK was studied using a p38 inhibitor
SB203580 (10 μM, Sigma Aldrich, St. Louis, MO, USA) which was applied 1 h before
TNF-α stimulation and present during the treatment.
Madej E., Lisek A., Brożyna A.A., Cierniak A., Wronski N., Deptula M., Wardowska A, & Wolnicka-Glubisz A. (2024). The involvement of RIPK4 in TNF-α-stimulated IL-6 and IL-8 production by melanoma cells. Journal of Cancer Research and Clinical Oncology, 150(4), 209.